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Introduction
Neuromyelitis optica (NMO) is an immune-mediated 
disorder of the central nervous system (CNS) in which 
the optic nerves and the spinal cord are preferentially 
involved.1 The disease-specific serum immunoglobu-
lin (Ig)G targeting the astrocyte water channel aqua-
porin-4 (AQP4)2,3 has facilitated differentiation of 
NMO from multiple sclerosis (MS) and recognition 
of a broad phenotypic spectrum referred to as neuro-
myelitis optica spectrum disorders (NMOSD).4 The 
use of the AQP4-IgG autoantibody in various in vivo 
and ex vivo models has led to an initial understanding 
of the pathogenic mechanisms that contribute to optic 
nerve injury.5 While additional autoantibodies against 
myelin oligodendrocyte glycoprotein (anti-MOG) 
and aquaporin-1 have been reported in a small num-
ber of NMO patients, the specificity of these autoanti-
bodies to NMO and their relationship to disease 
pathogenesis remain unclear.6–8
Techniques that provide information on the optic nerve 
structure and function are likely to prove useful 
to clinicians dealing with CNS diseases. Whereas a 
number of techniques evaluate visual function such as 
visual acuity, contrast sensitivity, color vision, visual 
fields, evoked potentials and pattern electroretino-
gram, others such as magnetic resonance imaging 
(MRI), optic coherence tomography (OCT), confocal 
scanning laser ophthalmoscopy (CSLO), and scanning 
laser polarimetry with variable corneal compensation 
(GDx-VCC), assess the anatomical integrity of the 
optic nerve and retina (Figure 1). OCT may have the 
advantage of requiring shorter acquisition times than 
CSLO,9,10 and is more sensitive than GDx-VCC11 in 
detecting retinal nerve fiber layer (RNFL) thinning in 
nasal and temporal sectors. It has the additional capa-
bility of measuring retinal segmental thickness.12,13
OCT is an analog of B-mode ultrasonography but 
uses infrared light instead of ultrasound to produce 
images based on the differential optical reflectivity. It 
can provide data on peripapillary and macular RNFL 
thicknesses and generate macular maps with segmen-
tal thicknesses and volumes (Figure 1). The recent 
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development of spectral domain OCT (SD-OCT) 
allows enhanced resolution (2 µm), shorter acquisi-
tion times, three-dimensional scans, and video imag-
ing.14,15 Also, eye tracking systems permit almost 
perfect repositioning in longitudinal studies, allowing 
investigators to capture subtle changes on the order of 
a few micrometers. Investigations in MS have dem-
onstrated that OCT is easy to perform, reproducible, 
and provides downstream measures of secondary neu-
rodegeneration (RNFL and macular thinning).12,16–19
Optic neuritis (ON) is a common condition involving 
primary inflammation, demyelination, and axonal injury 
in the optic nerve.20 This process may lead to retinal gan-
glion cell (RGC) death, decreased macular volume, and 
to visual dysfunction or permanent visual loss. ON usu-
ally presents as an acute episode of unilateral or less fre-
quently bilateral optic nerve inflammation, accompanied 
by ocular pain and decreased vision. ON is immune 
mediated21 and, in NMOSD, is associated with detecta-
ble AQP4-IgG.22 The pathological features of NMOSD 
Figure 1. Retinal parameters acquired by OCT.
(a) Fundus image showing the acquisition of the peripapillary RNFL thickness. OCT records a ring scan of 3.4 mm diameter around the 
optic nerve head, which is divided into quadrants. (b) The total macular volume is derived from a volume scan and contains all retinal 
layers in a 6 mm diameter cylinder around the fovea centralis. (c) Intra-retinal layer segmentation in a spectral domain OCT image. (d) 
MME in a patient with optic neuritis. MME locations are marked by yellow arrows.
OCT: optical coherence tomography; RNFL: retinal nerve fiber layer; S: superior; N: nasal; I: inferior; T: temporal; TMV: total macular 
volume; GCL; ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; OPL: outer plexiform layer; ONL: outer nuclear 
layer; ELM: external limiting membrane; IS/OS: inner segments/outer segments of the photoreceptor layer; RPE: retinal pigment 
epithelium; MME: microcystic macular edema.
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include deposition of IgG and activated complement, 
loss of AQP4 expression, astrocytopathy, neutrophil 
accumulation and demyelination with axon loss.23,24 The 
frequent involvement of the optic nerve in MS and NMO 
may be caused by a more reduced blood-brain barrier 
(BBB) function.25,26 Furthermore, the optic nerve 
expresses high levels of supramolecular aggregates of 
AQP4.27 The combination of enhanced AQP4 supramo-
lecular aggregation and heightened BBB permeability 
may contribute to the specific pattern of tissue damage in 
NMOSD. Objective measures of the severity and etiol-
ogy of optic nerve injury is important for the diagnosis, 
management, and treatment of ON. NMOSD-ON differs 
clinically from MS-ON; bilateral involvement is more 
common, and recurrent ON and severe residual visual 
dysfunction more likely.7,28–32 Common MRI imaging 
features include lesions extending over one-half the 
length of the optic nerve, posterior nerve involvement, 
and chiasmal inflammation.33,34 Whereas many charac-
teristics of OCT in MS have already been established 
and are consistent with its pathophysiology,35–40 OCT 
features in NMOSD are currently ill-defined and the 
relationship of these abnormalities with disease patho-
physiology remains unclear.41–51
This review analyzes the published data on OCT in 
NMOSD so that its ability to quantify optic nerve 
damage, facilitate diagnosis, monitor disease progres-
sion, evaluate therapeutic efficacy, and detect novel 
pathology might be assessed.
Methods
A literature search of Ovid MEDLINE (1946–2014) 
was conducted using the search terms “neuromyelitis 
optica” combined with “optical coherence tomogra-
phy.” Given that OCT is a newer technology, all arti-
cles were current (2008–present). Review articles and 
case reports were excluded; however, the references 
contained in such articles were reviewed for com-
pleteness. PubMed was also searched using similar 
methodology. Only studies available in English were 
included. Authors were not contacted for unpublished 
data. A comprehensive overview of the individual 
studies is given in the supplementary table.
OCT findings in NMOSD
RNFL and macula
OCT has been applied to NMOSD cohorts, initially in 
cross-sectional studies46–48 and, more recently, in pro-
spective longitudinal investigations.52 Cross-sectional 
studies have consistently shown that the RNFL is sig-
nificantly altered in NMOSD patients with ON 
compared to healthy controls and that RNFL thinning 
may be an early and frequent phenomenon. 
NMOSD-ON affects the entire peripapillary RNFL 
with particular involvement of the superior and infe-
rior quadrants 43,45 (Table 1 and Figure 2). This may 
reflect a lower preference for small-diameter axons, 
which are more abundant in the temporal quadrant 
and are preferentially affected in MS-ON.36,53 Macular 
thinning is more severe in NMOSD with ON than in 
MS-ON, in line with poorer visual recovery observed 
following ON in NMOSD. NMOSD patients with a 
history of ON tend to have significantly lower RNFL 
thicknesses than patients with MS-ON42–45 (Table 1 
and Figure 2). A meta-analysis showed that ON sig-
nificantly affects RNFL integrity and, on average, 
leads to a loss of approximately 20 µm in the affected 
eye in relapsing–remitting MS (RRMS) compared to 
healthy controls.36 A recent study by Green and Cree 
showed an average RNFL loss in MS-ON of 17.6 µm 
compared to an average 31.1 µm reduction in 
NMOSD-ON.44 Several studies showed that RNFL 
thickness in NMOSD patients after ON is reduced to 
55–83 µm, compared to 93–108 µm in the respective 
control groups.42,43,45–48,50,54–57
OCT measures and visual function
As in patients with MS, OCT in NMOSD correlated 
well with results from visual acuity testing.42,45 Using 
1.25% low-contrast visual acuity charts in monocular 
testing, the average number of correct letters read by 
NMOSD patients with ON was four; MS-ON patients 
and healthy controls averaged 6.5 and 16, respec-
tively.42 The same study indicated that high-contrast 
acuity became very poor in eyes of NMOSD patients 
with ON when the average RNFL thickness fell below 
60 µm.42 More recent studies applying macular multi-
layer segmentation analyses have provided evidence 
that not only peripapillary RNFL but also neuronal 
layers like the ganglion cell layer (GCL) or the com-
bined ganglion cell/inner plexiform layer (GCIP) are 
significantly thinned in patients with MS-ON and 
NMOSD-ON; the NMOSD patients showed greater 
thinning57,58 (Figure 2).
OCT measures in NMOSD eyes without ON
While in eyes of MS patients without a history of ON 
RNFL thickness is on average reduced by 7 µm,36 sev-
eral studies showed that NMOSD patients without a 
history of ON had normal RNFLs.42,46,48,50 This sug-
gests that subclinical ON in NMOSD is uncommon 
and contrasts with both the subclinical visual-evoked 
potential (VEP) abnormalities and OCT abnormali-
ties recognized in clinically isolated syndrome (CIS) 
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patients with or without clinical ON.19 Interestingly, 
another study reported that NMOSD eyes without a 
history of ON had prolonged P100 latencies on VEP 
compared to normal controls; however, the absolute 
latencies were still within the normal range.59 Other 
groups have reported thinning of the combined GCIP 
in NMOSD eyes without a history of ON.55,56 This 
discrepancy may result from difficulties in accurately 
ascertaining clinical ON events in a retrospective 
approach, differences in OCT devices, segmentation 
techniques, and the smaller variance of the GCIP met-
ric. Some differences in segmental retinal thinning 
has been observed in NMOSD-ON and MS-ON eyes, 
suggesting that SD-OCT may be useful in distinguish-
ing NMO from MS following ON.51 Additional inves-
tigations are needed, however, to confirm these 
preliminary observations.
Macular changes including microcystic macular 
edema (MME)
Some but not all OCT studies have also highlighted 
macular changes following MS-ON and RNFL 
changes following ON in NMOSD. These differences 
could reflect different pathogenic processes.54 MME 
has recently been described in patients with MS and 
other optic neuropathies (Figure 1(d)). In MS patients, 
MME seems to be associated with higher levels of 
clinical disability60 and disease activity as measured 
by the frequency of clinical relapses and MRI activity 
(T2- and gadolinium-enhancing T1 lesions).61 
Although the underlying mechanisms of MME are 
still a matter of debate,62 clinical reports have shown 
that MME is not MS-ON specific but can also be 
detected in NMOSD-ON eyes and other optic 
neuropathies (chronic relapsing inflammatory optic 
neuropathy, ischemic, Leber disease, etc.). Microcystic 
inner nuclear layer abnormalities can be detected in 
20%–26% of NMOSD patients,49,56,58 and in up to 
40% of ON-affected eyes in AQP4-IgG-positive 
patients but not in unaffected eyes.63 This is much 
higher than the 5% previously reported in MS 
patients.60,49
OCT measures and clinical disability
Similar to studies of MS-ON, visual function corre-
lates well with RNFL thickness36,46–48 in NMOSD 
patients. However, in contrast to some studies of 
MS-ON,13,64,65 RNFL thickness in NMOSD has only 
Table 1. Summary of neuro-ophthalmological parameters in neuromyelitis optica compared to multiple sclerosis.
NMO-ON MS-ON HCs Comments
Visual impairment Severe Moderate – Visual acuity and contrast sensitivity 
recovery after ON attacks in NMO is lower 
than in MS, and blindness is not uncommon 
in NMO; altitudinal loss may be eventually 
seen in NMO, but not in MS
Funduscopy Disc atrophy and 
vascular changes 
with ‘frosting’
Segmental disc 
atrophy without 
venous sheathing
– Vascular changes seen in eyes with ON 
in NMO: attenuation of arterioles in the 
peripapillary retina, often with accompanying 
venous changes
Optic nerve OCTa Reduction of peripapillary RNFL thickness in 
NMO is basically attack-related; MS patients 
may have RNFL reduction in non-ON eyes. 
Superior and inferior RNFL predominantly 
affected in NMO compared to temporal 
RNFL in MS.  
  Average RNFL 
thickness
55–83 µm 74–95 µm 93–108 µm
 Superior 66–100 µm 90–117 µm 121–136 µm
 Inferior 64–99 µm 92–117 µm 127–138 µm
 Temporal 39–63 µm 50–67 µm 67–79 µm
  Nasal 29–75 µm 42–88 µm 74–97 µm
Maculab Retinal thickness, total macular volume, and 
GCL/GC+IPL thickness are usually lower 
in affected eyes from NMO than MS, while 
INL/INL+OPL is often thicker in NMO.
Microcystic macular 
edema (MME)
20–26% 5–6% 0% MME eyes have lower pRNFL thickness, and 
VA than non-MME eyes
a RNFL segmentation from different optical coherence tomography (OCT) devices is slightly different, but comparable. bMacula thickness, total macular volume 
and intra-retinal layer segmentation varies in different machines; thus, results cannot be compared. NMO: neuromyelitis optica; MS: multiple sclerosis; HCs: 
healthy controls; ON: optic neuritis: RNFL: retinal nerve fiber layer; GCL: ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; OPL: outer 
nuclear layer.
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sporadically correlated with the overall Expanded 
Disability Status Scale (EDSS).46 Although this may 
not be surprising in light of the limited amount of 
visual function captured in the EDSS, the weaker cor-
relation between RNFL thickness and EDSS in 
NMOSD as compared to MS may be the product of 
both distinct pathophysiology and involvement of a 
more limited spectrum of the CNS neuroaxis. The 
development of a validated disability scale specific to 
NMOSD will be important in determining whether 
OCT parameters may extend beyond the visual sys-
tem to prove a clinical biomarker of disease activity.
ON and OCT in pediatric NMO
While most clinical characteristics of pediatric NMO 
are similar to adult-onset disease, a comprehensive 
clinical evaluation of NMOSD-ON in children has 
not been conducted. Approximately 50% of pediatric 
NMO cases have severe residual visual impairment in 
one or both eyes.66 However, the vast majority of 
cases involve recurrent episodes of ON. Since MRI 
examinations and VEPs can be challenging in chil-
dren because of a lack of patient cooperation, OCT 
may be a promising tool to differentiate pediatric 
NMO from other causes of ON. A longitudinal analy-
sis of NMOSD-ON in the pediatric population with 
accompanying OCT analysis will be critical for 
understanding whether visual outcomes and corre-
sponding neuro-anatomic measures of injury vary in 
the pediatric age group and powering clinical trials 
for acute and prophylactic therapies. 
Association of OCT measures with brain volume
Animal models have demonstrated that RNFL thin-
ning as measured by OCT reflects retinal axonal 
loss.67–69 Recent studies on OCT/MRI correlations in 
Figure 2. Typical differences in retinal damage between NMO-ON and MS-ON.
(a) RNFL thickness values for different locations of the peripapillary ring scans including comparison to a healthy reference group. (b) 
Thickness map of the retinal GCL, derived with help of a semiautomatic segmentation software. The NMO-ON patient shows more 
severe thinning both in the RNFL and GCL.
MS: multiple sclerosis; ON: optic neuritis; NMO: neuromyelitis optica; RNFL: retinal nerve fiber layer; GCL: ganglion cell layer.
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MS have shown good correlation between RNFL 
measures and both white and gray matter atrophy17,70 
and brain parenchymal fraction.71 Another recent 
study in a cohort of CIS and early RRMS patients with 
short disease duration (3.2 years) and mild levels of 
disability (median EDSS 1.5) indicated that in early 
stages of relapsing forms of the disease, OCT-derived 
retinal measures reflect white matter damage, with 
variability in gray matter being an age-related effect.72 
von Glehn et al. demonstrated cortical thinning in 
NMO patients (1.55 mm) compared to healthy con-
trols (1.62 mm, p = 0.027) and a positive correlation 
between RNFL and cortical thickness.73 When strati-
fied by disease duration, RNFL and cortical thinning 
both progressed with time. Additional MRI analyses 
demonstrated global white and gray matter volume 
loss.
Effect of relapse treatment on OCT measures and 
visual function
Recent therapeutic studies found that relapse activity 
in NMO patients responded better to immunosup-
pressive drugs than to immunomodulators.74–77 
Immunosuppressive drugs are known to have anti-
inflammatory effects, but to date there are no data 
regarding their effect on neuronal and axonal loss. 
One study compared intravenous methylpredniso-
lone (IVMP, 2 g per day for three to five days) to 
IVMP in conjunction with plasma exchange (PE, five 
consecutive exchanges) in individuals with a first 
attack of ON due to NMO or NMOSD.78 In the PE 
group, 75% recovered to 20/40 or better. While the 
Snellen equivalent did not improve in the IVMP-only 
group (20/400 at initial and end of study exams), the 
visual acuity in the PE group improved from 20/400 
at baseline to 20/50 at the final visit. While high-con-
trast visual acuity scores were better in the PE group, 
there were no statistical differences in RNFL thick-
ness (mean thickness 63 µm in the IVMP group vs. 
70 µm in the IVMP plus PE group, p = 0.16). A sec-
ond study performed in patients who had failed to 
improve with high-dose corticosteroids also exam-
ined the use of PE.79 In this small study, RNFL thick-
ness was preserved at one year, with one patient 
followed longitudinally and demonstrating stable 
RNFL thickness over four years. Another small retro-
spective study from Japan suggested that early IVMP 
treatment after an acute ON event may help preserve 
RNFL thickness in NMO.45 Eyes with RNFL thick-
nesses exceeding 71.41 µm had a significantly earlier 
treatment with IVMP than those eyes below this cut-
off. Average RNFL thickness after an ON attack was 
inversely correlated with the period from onset of 
clinical symptoms to IVMP therapy. Thus, because of 
its sensitivity, OCT is a noninvasive tool that is 
ideally suited to provide information on potential 
neuroprotection in ON clinical trials.45,80
Value of OCT for differential diagnosis
In light of different treatment strategies for NMOSD 
and MS, an early and accurate diagnosis is key for opti-
mal patient management but may remain challenging 
in cases of seronegative NMO. In this regard, OCT 
may be of potential value to help the clinician discrimi-
nate between MS-ON and NMOSD-ON, particularly 
when ON is the initial clinical presentation. Some stud-
ies have analyzed the ability of OCT measures to dis-
tinguish between MS and NMOSD. Naismith et al. 
reported that the odds of falling into the NMOSD group 
increased by 8% for every 1 µm decrease in RNFL 
thickness.43 In a multilayer segmentation study, Park et 
al. found that ONL thickness greater than 83 µm at the 
inner temporal location (from the foveal center) and 
GCIP thickness of less than 62 µm at the outer superior 
location (from the foveal center) were suggestive of 
NMO.57 Schneider et al. reported that both peripapil-
lary RNFL thickness and the ratio of nasal to temporal 
peripapillary RNFL thickness may be helpful in distin-
guishing NMOSD-ON and MS-ON.50 However, each 
of these findings has to be interpreted with caution 
given the low sample sizes and the exploratory nature 
of the analyses. Confirmatory studies using larger 
patient populations are needed before they can be used 
to guide clinical decision making.
Future prospects
Major advancements in the management of brain dis-
ease are likely to depend on the identification of 
imaging or molecular biomarkers. Such biomarkers 
are needed for an improved understanding of the 
pathogenesis, the stratification of patients based on 
the prognosis or response to therapy, and as surrogate 
endpoints in clinical trials. As such, one of the main 
initiatives from the National Institutes of Health 
(NIH) in Alzheimer’s disease is a multicenter study 
for validating biomarkers (MRI, positron-emission 
tomography (PET), beta-amyloid or Tau in cerebro-
spinal fluid (CSF)). For this reason, OCT for quanti-
fying and monitoring axon damage of the optic nerve 
and the related retrograde degeneration of the GCL is 
likely to improve assessment of optic nerve tissue 
damage in NMO-ON. Although OCT will not capture 
non-optic nerve damage, its exquisite ability to quan-
tify changes in the retina after optic nerve damage 
may allow prediction of visual recovery, general 
assessment of therapeutic efficacy as a surrogate of 
disability after inflammatory attacks or as a measure 
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of neuroprotection or regeneration, and stratification 
of patients based on different patterns of damage.
Multimodal and comprehensive evaluation of the 
anterior visual pathway will provide even better 
understanding of NMOSD patients with ON. It may 
deliver clinically useful instruments for patient analy-
sis. The good agreement between morphology cap-
tured by OCT, functional assessments such as 
multifocal visual-evoked potentials, and clinical out-
comes such as visual fields, visual acuity and visual 
quality of life, may enable a comprehensive assess-
ment of ON in patients with NMOSD. Moreover, 
multimodal assessments of patients provide the 
opportunity to integrate all factors participating in the 
disease, from molecular and cellular processes to vis-
ual system performance. New laser technologies are 
being developed that will allow molecular analysis of 
the retina changes, single-cell visualization of the 
RNFL and RGC, assessment of neural activity by 
imaging (which can be integrated with electroretinog-
raphy), changes in blood flow and other retina fluids. 
NMO, an AQP4-astrocytopathy that commonly 
affects the optic nerves, is likely to benefit from these 
developments. For this reason, NMO can effectively 
indicate the potential of this new technology in assess-
ing CNS damage and of neuroprotective or regenera-
tive treatments.
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